Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen
Blood(2021)
摘要
Background. Risk stratification is particularly important to tailor the therapeutic strategy and avoid unnecessary toxicity for the treatment of relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). Early assessment of chemo-sensitivity by fluoro-deoxy-glucose ([18F]FDG) positron emission tomography (PET) scan is the strongest predictor of outcome in first line setting; however, data are limited in r/r cHL. Circulating tumor DNA (ctDNA) profiling is emerging as a powerful tool for outcome prediction and response monitoring.The BEGEV (BEndamustine, GEmcitabine,Vinorelbine) regimen is routinely offered as salvage strategy prior to autologous (auto) or allogeneic (allo) stem cell transplantation (SCT) in r/r cHL (Santoro, 2016). Early identification of patients who fail this program may have a significant clinical impact in the selection of the optimal therapeutic strategy for r/r cHL.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要